Free shipping on all orders over $ 500

Aflibercept

Cat. No. M3849

All AbMole products are for research use only, cannot be used for human consumption.

Aflibercept Structure
Size Price Availability Quantity
1mg USD 800  USD800 In stock
2mg USD 1000  USD1000 In stock
5mg USD 1800  USD1800 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Aflibercept is a vascular epidermal growth factor (VEGF-A and PlGF) receptor inhibitor that inhibits the growth of neovascularization. It can be used to study a variety of diseases caused by ocular neovascularization. Aflibercept is a recombinant fusion protein consisting of vascular endothelial growth factor (VEGF)-binding portions from the extracellular domains of human VEGF receptors 1 and 2, that are fused to the Fc portion of the human IgG1 immunoglobulin.

Chemical Information
Molecular Weight 96896.92
Formula C4318H6788N1164O1304S32
CAS Number 862111-32-8
Storage -80°C for long term
References

[1] María Rodríguez-Remírez, et al. Neuroendocrinology . Strong Antitumor Activity of Bevacizumab and Aflibercept in Neuroendocrine Carcinomas: In-Depth Preclinical Study

[2] Lisa-Marie Muellerleile, et al. Res Vet Sci. In-vitro binding analysis of anti-human vascular endothelial growth factor antibodies bevacizumab and aflibercept with canine, feline, and equine vascular endothelial growth factor

[3] Charlotte V Fischer, et al. Invest Ophthalmol Vis Sci. The Antiproliferative Effect of Bevacizumab on Human Tenon Fibroblasts Is Not Mediated by Vascular Endothelial Growth Factor Inhibition

[4] Sarwar S, et al. Cochrane Database Syst Rev. Aflibercept for neovascular age-related macular degeneration.

Related Fusion Proteins Products
Conbercept

Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc.

Evorpacept

Evorpacept (ALX148) is a high affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region designed to enhance the activity of other anti-neoplastic therapies, with minimal additional toxicity.

Belatacept

Belatacept (BMS 224818) is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. Belatacept binds to CD 80/86 ligands and thereby inhibits the CD-28-mediated T-cell costimulation. Belatacept can be used in the research of Immunosuppression in organ transplants.

Baminercept

Baminercept (BG 9924) is a lymphotoxin β receptor IgG fusion protein (LTβR-Ig). Baminercept can be used for the research of many autoimmune diseases including primary Sjögren's syndrome (SS) and rheumatoid arthritis (RA) .

Briobacept

Briobacept (BR 3FC) is a selective human monoclonal antibody targeting to BLyS (BAFF), induces B cells apoptosis. Briobacept is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept can be used in studies of rheumatoid arthritis (RA).

  Catalog
Abmole Inhibitor Catalog




Keywords: Aflibercept supplier, Fusion Proteins, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.